share_log

HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $1

HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $1

HC Wainwright & Co.維持對SAB Biotherapeutics的買入,將目標價下調至1美元
Benzinga ·  2023/11/14 13:46

HC Wainwright & Co. analyst Edward White maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and lowers the price target from $2 to $1.

HC Wainwright & Co. 分析師愛德華·懷特維持SAB Biotherapeutics(納斯達克股票代碼:SABS)的買入,並將目標股價從2美元下調至1美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論